Cerebrolysin 30mg
€ 59,00 Original price was: € 59,00.€ 54,00Current price is: € 54,00.
Cerebrolysyn 30 mg – Grail Formula Quality.
Researched and verified with Liquilabs s.r.o. Czechia.
Analytical testing reports total protein content greater than 100 % by the Modified Biuret Method, bacterial endotoxin measured at 0.034 EU/mg, and microbiological counts of 0 CFU/g. Individual peptide identity and chromatographic purity were not established by this COA.
Supplied as a nominal 30 mg peptide-associated research preparation with batch-specific COA traceability.
For research use only — not for human or veterinary use.
Availability: In stock: ships within 1 day after payment confirmation.
| Secure Transaction |
Cerebrolysyn 30 mg is a peptide-associated research preparation supplied by Grail Formula for scientific investigation and controlled laboratory experimentation involving peptide mixtures, protein-derived compounds, analytical biochemistry and experimental neurobiology.
For research use only — not for human or veterinary use.
Product Overview
Cerebrolysyn 30 mg is supplied as a nominal 30 mg research preparation for laboratory investigations involving protein-derived peptide materials, biochemical characterisation and peptide-associated molecular research.
Cerebrolysyn belongs to a category of research materials associated with complex peptide and protein-derived preparations. Unlike a single synthetic peptide with one defined amino acid sequence, such materials may contain multiple molecular components requiring different analytical approaches for complete characterisation.
Scientific interest in peptide mixtures extends to molecular composition, protein degradation products, peptide fragment analysis, chromatographic profiling and interactions between peptide-derived components and experimental biological systems.
Grail Formula provides Cerebrolysyn 30 mg with independent third-party analytical documentation from Liquilabs s.r.o., Czechia.
The Certificate of Analysis was published on 7 October 2026 and identifies batch GF-CERE30-B242, laboratory sample LYO-0671.
The report documents total protein content assessment, bacterial endotoxin determination, microbiological counts and screening for seven elemental impurities.
Total protein content was reported as greater than 100 % using a modified Biuret method. The supporting analytical report displays a calculated concentration result of 31.02 for the tested sample.
The reported percentage is a method-derived result and should not be interpreted as a chromatographic purity measurement, an exact peptide assay or confirmation of individual peptide quantities.
The Certificate of Analysis does not provide a complete molecular composition, individual peptide sequences or separate identification results for specific peptide components.
Peptide Overview
Peptides are molecular structures composed of amino acids connected through peptide bonds. They vary considerably in molecular length, sequence, charge, structural characteristics and physicochemical behaviour.
Peptide research includes the investigation of individual synthetic peptides, naturally occurring peptide fragments and complex mixtures containing multiple peptide-associated molecular species.
Protein-derived peptide preparations are of particular interest in analytical biochemistry because their composition may reflect the original protein source, processing conditions and the molecular characteristics of the resulting fragments.
Unlike single-sequence research peptides, complex peptide preparations cannot necessarily be represented by one molecular formula, one molecular mass or one chromatographic purity percentage.
Detailed characterisation may require multiple complementary analytical techniques, including chromatography, mass spectrometry, peptide mapping and quantitative protein or peptide assessment.
In experimental neurobiology, researchers investigate peptide-associated molecular processes involving neuronal cell signalling, protein interactions, intracellular communication and cellular responses to defined laboratory conditions.
These scientific areas provide context for research involving peptide-derived materials. However, the specific molecular composition and biological properties of the Grail Formula Cerebrolysyn batch have not been established by the supplied Certificate of Analysis.
The reported total protein content measurement provides analytical information about the tested preparation but does not identify individual peptide fragments or establish their relative concentrations.
Researchers should distinguish between total protein-associated measurements and compound-specific identity analysis when evaluating complex peptide research materials.
Historical Background and Scientific Context
Scientific investigation of peptides developed alongside advances in protein chemistry, amino acid analysis and the understanding of molecular processes involving proteins and their fragments.
Early peptide research focused on identifying amino acid sequences, understanding peptide bond formation and examining the relationship between molecular structure and biological activity.
As analytical techniques improved, researchers gained the ability to investigate increasingly complex peptide mixtures and protein-derived molecular fractions.
The development of chromatographic separation methods provided important tools for studying peptide composition, while mass spectrometry enabled more detailed molecular mass determination and peptide identification.
Research involving protein-derived peptide fractions subsequently expanded into biochemistry, molecular biology and experimental neuroscience.
In neurobiological research, peptide-associated molecular systems have been investigated in connection with cellular communication, neuronal signalling and interactions between proteins, peptides and intracellular regulatory pathways.
Researchers have also examined the analytical challenges associated with complex peptide preparations, including variability in molecular composition, differences in fragment distribution and the interpretation of bulk protein measurements.
These considerations are particularly important when a research material is described by a nominal total quantity rather than a fully defined molecular composition.
Modern peptide research increasingly emphasises reproducibility, analytical traceability and the use of complementary methods to characterise complex molecular preparations.
For materials containing multiple peptide-associated components, a total protein assay can provide useful information about the overall sample response but cannot replace compound-specific identity testing.
Research into peptide mixtures therefore involves both biological investigation and analytical methodology development.
Cerebrolysyn can be considered within this broader scientific context of peptide-associated research materials, while recognising that the supplied COA does not establish its precise constituent peptides or specific biological mechanisms.
Mechanistic Focus in Research
Research involving complex peptide preparations may address several molecular and biochemical processes, depending on the composition of the material and the experimental model employed.
Because the supplied Cerebrolysyn Certificate of Analysis does not identify individual peptide components, no specific receptor interaction or biological mechanism can be assigned to this batch on the basis of the report alone.
Peptide and protein fragment characterisation
One important area of research concerns the identification and characterisation of peptide fragments derived from larger protein structures.
Researchers examine molecular mass distributions, amino acid composition and chromatographic behaviour to better understand the chemical characteristics of complex peptide materials.
These investigations can contribute to the development of analytical methods for distinguishing individual components within heterogeneous molecular preparations.
Experimental neuronal signalling research
Peptides and protein-derived molecules are investigated in experimental neurobiology because many naturally occurring signalling systems involve peptide-associated molecular interactions.
Laboratory research may examine receptor-associated signalling, intracellular communication and the behaviour of peptide-containing materials in defined cellular systems.
However, such research directions should not be interpreted as evidence that this specific Cerebrolysyn batch produces any particular neuronal response.
Cellular protein interactions
Another area of scientific interest involves the interaction of peptide-derived molecules with proteins, membranes and intracellular molecular structures.
These interactions may depend on peptide sequence, molecular charge, structural organisation and the physicochemical characteristics of the experimental environment.
Without component-specific analytical identification, these interactions cannot be attributed to particular molecular species within the tested preparation.
Analytical protein quantification
Protein concentration assessment is an important component of biochemical laboratory research.
The Biuret method is based on the formation of a coloured complex involving copper ions and peptide bonds under alkaline conditions. The resulting spectrophotometric response can be used for protein-associated quantification against suitable calibration standards.
Modified Biuret procedures may be used to evaluate total protein-associated responses in laboratory samples.
For the Cerebrolysyn preparation, Liquilabs reported a total protein content result greater than 100 % using a modified Biuret method.
The interpretation of this result depends on the analytical calibration, reference standard and calculation method. It does not establish the purity or concentration of every individual molecular component.
Research reproducibility and analytical profiling
Complex peptide preparations may require detailed analytical profiling to support reproducibility between experimental samples and production batches.
Complementary techniques such as liquid chromatography, mass spectrometry and peptide mapping can provide additional information beyond a total protein assay.
These techniques are discussed as relevant analytical research methods and are not presented as tests completed for this Cerebrolysyn batch.
Analytical Verification (COA)
Grail Formula provides batch-specific analytical documentation through independent testing conducted by Liquilabs s.r.o., Czechia.
The Cerebrolysyn 30 mg Certificate of Analysis was published on 7 October 2026 and identifies batch GF-CERE30-B242, laboratory sample LYO-0671.
The five-page report contains total protein content analysis, bacterial endotoxin results, microbiological testing and elemental impurity screening.
Total protein content assessment
- Nominal product quantity: 30 mg
- Reported total protein content: greater than 100 %
- Analytical method: Modified Biuret Method
- Screening designation: Polar Compound Screening 10 mM ammonium formate buffer
- Supporting analytical concentration result: 31.02, as displayed in the laboratory report
- Supporting instrument: UV-1900i Series
The supporting analytical documentation includes a spectrophotometric calibration curve and a sample measurement table.
The reported result greater than 100 % requires interpretation in the context of the modified Biuret method and its calibration procedure.
The value must not be represented as greater than 100 % chemical purity or as a compound-specific assay.
The supporting concentration value of 31.02 is reproduced without assigning an unconfirmed mass unit or treating it as a verified 31.02 mg peptide content measurement.
Identity and composition assessment
The Certificate of Analysis does not report individual peptide identification, chromatographic purity, FTIR identity results, retention time identification or molecular ion mass determination.
It also does not provide an amino acid sequence, peptide mapping results or a quantitative breakdown of individual molecular components.
Consequently, the report supports a limited analytical description of the preparation rather than complete molecular characterisation.
Bacterial endotoxin assessment
- Bacterial endotoxin: 0.034 EU/mg
- Reported uncertainty: ± 0.001 EU/mg
- Laboratory acceptable range: 0–0.5 EU/mg
- Analytical reference: USP <85> / European Pharmacopoeia 2.6.14
- Method: Chromogenic bacterial endotoxin testing
The measured bacterial endotoxin concentration of 0.034 EU/mg falls within the laboratory’s stated acceptable range.
This result describes the tested sample under the applied analytical conditions and does not establish sterility or suitability for administration.
Microbiological assessment
- Total aerobic microbial count: 0 CFU/g
- Total yeast and mould count: 0 CFU/g
- Reported aerobic microbial count range: 0–1000 CFU/g
- Reported yeast and mould count range: 0–100 CFU/g
- Analytical reference: USP <61> / European Pharmacopoeia 2.6.12
- Method: Plate-count testing
Both microbiological counts were reported as zero under the laboratory’s testing conditions.
The accompanying method documentation describes sample preparation, culture media, incubation conditions and the calculation of colony-forming units.
These measurements represent the reported findings for the tested sample and do not establish the absence of every possible microorganism.
Elemental impurity screening
Seven elemental impurities were evaluated using procedures referenced to USP <232> and European Pharmacopoeia 5.20 / 2.4.20.
- Arsenic: below 0.001 ppm
- Cadmium: below 0.001 ppm
- Mercury (listed as quicksilver): below 0.001 ppm
- Lead: below 0.001 ppm
- Nickel: below 0.001 ppm
- Vanadium: below 0.001 ppm
- Cobalt: below 0.001 ppm
All seven reported elemental impurity results were below 0.001 ppm and within the laboratory’s stated acceptable ranges.
A result below the analytical reporting threshold indicates a concentration below that level rather than absolute absence of the element.
The complete five-page Certificate of Analysis includes the summary results, supporting protein-content calibration data and microbiological testing methodology.
Research Applications
Cerebrolysyn 30 mg may be relevant to laboratory investigations involving complex peptide-associated preparations, protein quantification and analytical research methodology.
The precise scope of any component-specific biological investigation depends on additional molecular characterisation and the design of the experimental system.
Potential areas of laboratory investigation include:
- Complex peptide mixture characterisation
- Protein-derived molecular fraction research
- Modified Biuret protein quantification methods
- Experimental peptide-associated neurobiology
- Analytical comparison of protein-containing research materials
- Biochemical research involving peptide fragment distribution
- Laboratory method development for complex peptide preparations
- Microbiological and elemental impurity assessment of research samples
These areas describe scientific research directions rather than verified biological activities of the tested batch.
Additional analytical identification would be required before assigning specific molecular targets or individual peptide-associated mechanisms to the preparation.
Grail Formula Quality
Grail Formula focuses on providing laboratory research compounds accompanied by transparent product information and independently documented analytical findings.
For Cerebrolysyn 30 mg, Liquilabs testing provides information concerning total protein content, bacterial endotoxin concentration, microbiological counts and selected elemental impurities.
The reported protein content greater than 100 % is presented as a method-specific analytical result rather than an unsupported purity claim.
Each measurement should be interpreted within the scope of the tested sample, the analytical methodology and the limitations of the available Certificate of Analysis.
Transparent reporting of available results and unmeasured characteristics supports responsible laboratory documentation.
When You Choose Grail Formula
Grail Formula provides Cerebrolysyn 30 mg with independent batch-specific analytical documentation from Liquilabs s.r.o., Czechia.
Researchers can examine the reported protein-content measurement, endotoxin result, microbiological findings and elemental impurity screening associated with batch GF-CERE30-B242.
The Certificate of Analysis provides a defined laboratory sample reference and publication date for analytical traceability.
Grail Formula emphasises factual research product descriptions, transparent reporting and clear distinctions between measured analytical characteristics and properties that have not been established.
This approach supports laboratory researchers seeking documented information about the tested preparation without relying on unsupported purity, identity or biological activity claims.
Research Use Limitation
Used solely for in vitro experiments and cannot be:
- Used in clinical trials involving humans
- Administered to humans as part of an experiment or investigation
- Supplied to another party for human investigational use.
- Independently analysed by Liquilabs s.r.o. Czechia
- Cerebrolysyn research preparation with nominal 30 mg quantity
- Total protein content greater than 100 % reported by Modified Biuret Method
- Supporting analytical concentration result: 31.02, as reported
- Individual peptide identity and chromatographic purity not established by the COA
- Bacterial endotoxin level of 0.034 EU/mg ± 0.001 EU/mg
- Total aerobic microbial count: 0 CFU/g
- Total yeast and mould count: 0 CFU/g
- All seven reported elemental impurities below 0.001 ppm
- Batch number: GF-CERE30-B242
- Laboratory sample identification: LYO-0671
- COA publication date: 7 October 2026
- Independent batch-specific analytical documentation
- Research material for peptide-associated analytical biochemistry and laboratory investigations
- For research use only – not for human or veterinary use
For laboratory research only. Not intended for human consumption, injection, or cosmetic use.
This product is for research purposes only. Not for human use or diagnostic/therapeutic applications. Keep out of reach of children.
Third-Party Tested
Public COAs
Batch Verified
EU Shipping
Related Products
€ 139,00 Original price was: € 139,00.€ 124,00Current price is: € 124,00.